CivicaScript Launches Latest Generic, Plans to Introduce More Drugs in July

Jun 26
Jun 26, 2025

CivicaScript, a generic drug manufacturer founded in 2020 by several Blue Cross and Blue Shield plans, announced on June 24 the availability of dimethyl fumarate delayed-release capsules. The multiple sclerosis drug is the third medication that CivicaScript has introduced to the market, following abiraterone acetate for prostate cancer in August 2022 and droxidopa for hypotension two months ago. The company plans on launching another MS drug and an oncology medication next month, as well.

While CivicaScript has touted the savings and transparency associated with its products, pointing to a study published last month about abiraterone in the New England Journal of Medicine Catalyst, one longtime pharmacist and consultant claims the findings may be overstated.
Read more
© 2025 MMIT

Tim Casey

Tim has been a reporter and editor for newspapers, websites and magazines for more than 20 years, including 10 years covering health care business topics. He has a deep knowledge of the managed care industry and pharmacy benefit management. He also has experience covering medical conferences and clinical and legislative health care issues. In 2014, the Society for Advancing Business Editing and Writing selected Tim as one of 15 journalists to participate in a national symposium on the Affordable Care Act. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.